Pediatric Congenital Atrioventricular Block 

  • Author: Monesha Gupta, MD, MBBS, FAAP, FACC, FASE; more...
 
Updated: Dec 6, 2011
 

Background

Third-degree or complete atrioventricular block (CAVB) is seen either in the fetal life or anytime after birth with complete atrioventricular dissociation and bradycardia and is called congenital heart block to differentiate it from acquired third-degree heart block. It can occur in the fetal life due to maternal disease or due to a congenital heart defect in the fetus and can manifest at any given time before or after birth. CAVB can occur in a structurally normal heart (isolated CAVB) or with congenital heart disease (complex CAVB with congenital heart defects). (See Etiology.)

More recently, it has been recognized that the associations and prognosis of CAVB differ depending on whether the block is identified in the fetus, newborn, or older child.

Isolated CAVB occurs in the absence of other congenital heart defects. It usually is seen in association with certain autoimmune antibodies in the mother that cross the placenta and damage the atrioventricular (AV) node of the fetus. The mother can be completely asymptomatic in presence of these autoimmune antibodies or may have a diagnosis of an autoimmune disorder (eg, systemic lupus erythematosus, Sjögren syndrome). (See Etiology, Clinical, and Workup.)

Isolated CAVB can also occur due to myocarditis and rare hereditary conditions, such as storage disorders (eg, Hurler syndrome, Hunter syndrome). Often, no etiology is found for an isolated CAVB.

CAVB can also be seen with certain congenital heart defects, most often complex defects, such as heterotaxy with accompanying AV canal defects and L-transposition of the great arteries.

Complications

Long-term potential complications in all patients include development of ventricular dilatation and dysfunction. Patients without a pacemaker may develop AV valve regurgitation, atrial rhythm disorders, thromboembolism, congestive failure, or sudden death.[1] Patients with a pacemaker may develop pacing system–related complications, including lead fracture, malsensing, and pacing system infections. Replacement of pacemakers is required at intervals and can lead to complications from the procedure. Congenital complete heart block is an increasingly recognized cause of fetal loss. (See Prognosis and Treatment.)

Occurrence

Autoimmune AV block occurs in approximately 1 per 14,000-20,000 live births. However, because significant fetal loss is thought to result from this disease, the true incidence of the disease (per conception) may be significantly higher. Structural congenital heart block is also rare, but with a higher proportion of fetal loss. The prevalence of isolated CAVB may be slightly higher in females than in males.

Next

Etiology

CAVB with structural heart disease is considered to be caused by failure of the AV conduction system to develop during heart development. This may be a result of increased distance between the AV node and the ventricular conduction tissues, as when associated with structural congenital heart disease or damage related to the passage of maternal autoantibodies.

Isolated CAVB has been described since 1901. In some cases, since the early 1970s, it has been associated with the presence of maternal connective-tissue disease.

Autoimmune CAVB is presumed to be caused by injury from the placental passage of maternal anti-Ro and anti-La (or related) antibodies, which are present in more than 90% of mothers during pregnancy or at the time of delivery. These autoantibodies damage the AV conduction tissue possibly by inflammation or direct ion channel interaction in the early stage and later by fibrosis.[2, 3, 4]

CAVB occurs in as many as 5% of children born to mothers with anti-Ro antibody, which can be seen with subclinical or clinical maternal lupus erythematosus, maternal Sjögren syndrome, or another maternal autoimmune disease. After birth, the children may present with varying degrees of heart block, including CAVB, cardiomyopathy, and other manifestations of neonatal lupus syndrome. However, the majority of infants who are born to these mothers but do not manifest AV block.

Many times, no clear etiology is determined for isolated CAVB. Rarely, it can occur as a result of myocarditis, infiltrative disease, or other cardiomyopathy. Hereditary diseases such as Hurler cardiomyopathy and Hunter cardiomyopathy can be associated with CAVB.

Complex CAVB is associated with congenital heart defects that have structural abnormality of the conduction system. These heart defects are usually complex, such as L-transposition of great arteries.

Previous
Next

Prognosis

The prognosis in isolated complete CAVB is relatively good but may be influenced by the patient's age at presentation. Patients presenting as fetuses or at birth have significantly higher morbidity and mortality rates than do patients presenting later in childhood.[5]

Patients with L-transposition of the great arteries and other complex structural cardiac defects have a worse prognosis unless detected and treated early.

According to a long-term follow-up study by Michaelsson and colleagues, adults with complete CAVB who did not receive pacing systems had a poorer prognosis than did those with pacing because of multiple complications related to their disease.[1] Therefore, in the adolescent who has not yet developed indications for pacing (an unusual case), recommendations for a pacing system should be considered, regardless of symptoms or underlying escape rate.

Morbidity and mortality

The fetal mortality rate of isolated CAVB may be as much as 30-50%. Patients who are diagnosed and treated in the neonatal period have a survival rate of 94%, and patients who are diagnosed and treated in childhood have a survival rate of 100%.

Risk factors for death in patients with isolated CAVB include fetal diagnosis, very low heart rate, low birth weight, premature gestation, male gender, hydrops fetalis, endocardial fibroelastosis, and diminished ventricular function.

Hydrops fetalis is the risk factor for patients with structural heart disease and CAVB. Fetal and newborn mortality rates in congenital heart block with structural heart disease remain high, even if effective pacing is used.

Previous
Next

Patient Education

Parents who are at risk of having a child with CAVB must be informed that this disease is easily identifiable and relatively easily treated after birth. The stigma of pacing as a therapy associated with elderly persons should be avoided. Parents should recognize that their affected offspring are likely to receive and benefit from pacing therapy at some point during childhood but that pacemaker therapy is intentionally deferred until indications are present to preserve lifelong access for pacing systems.

Patients and their families should be instructed to avoid medications that can cause AV block (eg, calcium channel blockers, beta blockers).

Previous
 
 
Contributor Information and Disclosures
Author

Monesha Gupta, MD, MBBS, FAAP, FACC, FASE  Associate Professor of Pediatrics, Division of Pediatric Cardiology and Nephrology, Children's Memorial Hermann Hospital, University of Texas Medical School

Monesha Gupta, MD, MBBS, FAAP, FACC, FASE is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American Society of Echocardiography, Medical Council of India, Society for Pediatric Research, and Society of Pediatric Echocardiography

Disclosure: Nothing to disclose.

Coauthor(s)

Robert Murray Hamilton, MD, MSc, FRCPC  Section Head, Electrophysiology, Senior Associate Scientist, Physiology and Experimental Medicine, Labatt Family Heart Centre; Professor, Department of Pediatrics, University of Toronto Faculty of Medicine

Robert Murray Hamilton, MD, MSc, FRCPC is a member of the following medical societies: American Heart Association, Canadian Cardiovascular Society, Canadian Medical Association, Canadian Medical Protective Association, Cardiac Electrophysiology Society, Heart Rhythm Society, Ontario Medical Association, Pediatric Electrophysiology Society, Royal College of Physicians and Surgeons of Canada, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

Charles I Berul, MD Professor of Pediatrics and Integrative Systems Biology, George Washington University School of Medicine; Chief, Division of Cardiology, Children's National Medical Center

Charles I Berul, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American Heart Association, Cardiac Electrophysiology Society, Heart Rhythm Society, Pediatric and Congenital Electrophysiology Society, and Society for Pediatric Research

Disclosure: Johnson & Johnson Consulting fee Consulting

Alvin J Chin, MD Professor of Pediatrics, University of Pennsylvania School of Medicine; Attending Physician, Cardiology Division, Children's Hospital of Philadelphia

Alvin J Chin, MD, is a member of the following medical societies: American Association for the Advancement of Science, American Heart Association, and Society for Developmental Biology

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References
  1. Michaelsson M, Jonzon A, Riesenfeld T. Isolated congenital complete atrioventricular block in adult life. A prospective study. Circulation. Aug 1 1995;92(3):442-9. [Medline]. [Full Text].

  2. Claus R, Hickstein H, Kulz T, et al. Identification and management of fetuses at risk for, or affected by, congenital heart block associated with autoantibodies to SSA (Ro), SSB (La), or an HsEg5-like autoantigen. Rheumatol Int. Aug 2006;26(10):886-95. [Medline].

  3. Costedoat-Chalumeau N, Amoura Z, Villain E, et al. Anti-SSA/Ro antibodies and the heart: more than complete congenital heart block? A review of electrocardiographic and myocardial abnormalities and of treatment options. Arthritis Res Ther. 2005;7(2):69-73. [Medline].

  4. Costedoat-Chalumeau N, Georgin-Lavialle S, Amoura Z, et al. Anti-SSA/Ro and anti-SSB/La antibody-mediated congenital heart block. Lupus. 2005;14(9):660-4. [Medline].

  5. Weng KP, Chiou CW, Huang SH, et al. The long-term outcome of children with isolated congenital complete atrioventricular block. Acta Paediatr Taiwan. Sep-Oct 2005;46(5):260-7. [Medline].

  6. Jaeggi ET, Hornberger LK, Smallhorn JF, Fouron JC. Prenatal diagnosis of complete atrioventricular block associated with structural heart disease: combined experience of two tertiary care centers and review of the literature. Ultrasound Obstet Gynecol. Jul 2005;26(1):16-21. [Medline].

  7. Friedman DM, Kim MY, Copel JA, et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation. 2008;117:485-93. [Medline].

  8. Figa FH, McCrindle BW, Bigras JL, et al. Risk factors for venous obstruction in children with transvenous pacing leads. Pacing Clin Electrophysiol. Aug 1997;20(8 Pt 1):1902-9. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.